vs
Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
ADC Therapeutics SA is the larger business by last-quarter revenue ($23.1M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). On growth, ADC Therapeutics SA posted the faster year-over-year revenue change (36.4% vs -25.7%). Over the past eight quarters, ADC Therapeutics SA's revenue compounded faster (13.7% CAGR vs -15.9%).
ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
ADCT vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $18.7M |
| Net Profit | — | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | -77.7% | -6.9% |
| Net Margin | — | -0.8% |
| Revenue YoY | 36.4% | -25.7% |
| Net Profit YoY | — | 97.6% |
| EPS (diluted) | $0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.1M | — | ||
| Q3 25 | $15.8M | — | ||
| Q2 25 | $18.1M | $18.7M | ||
| Q1 25 | $17.4M | $50.9M | ||
| Q4 24 | $16.9M | $38.1M | ||
| Q3 24 | $18.0M | $33.4M | ||
| Q2 24 | $17.0M | $25.1M | ||
| Q1 24 | $17.8M | $41.5M |
| Q4 25 | — | — | ||
| Q3 25 | $-41.0M | — | ||
| Q2 25 | $-56.6M | $-154.0K | ||
| Q1 25 | $-38.6M | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | $-44.0M | $5.7M | ||
| Q2 24 | $-36.5M | $-6.5M | ||
| Q1 24 | $-46.6M | $13.8M |
| Q4 25 | -77.7% | — | ||
| Q3 25 | -196.6% | — | ||
| Q2 25 | -244.1% | -6.9% | ||
| Q1 25 | -163.5% | 44.4% | ||
| Q4 24 | -191.8% | 46.4% | ||
| Q3 24 | -197.4% | 12.3% | ||
| Q2 24 | -170.5% | -33.7% | ||
| Q1 24 | -188.3% | 28.1% |
| Q4 25 | — | — | ||
| Q3 25 | -260.1% | — | ||
| Q2 25 | -313.2% | -0.8% | ||
| Q1 25 | -221.8% | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | -244.1% | 17.2% | ||
| Q2 24 | -214.6% | -26.0% | ||
| Q1 24 | -261.1% | 33.3% |
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.50 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.42 | — | ||
| Q2 24 | $-0.38 | — | ||
| Q1 24 | $-0.56 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $261.3M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-185.8M | $119.9M |
| Total Assets | $323.1M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $261.3M | — | ||
| Q3 25 | $234.7M | — | ||
| Q2 25 | $264.6M | $49.0M | ||
| Q1 25 | $194.7M | $47.6M | ||
| Q4 24 | $250.9M | $38.1M | ||
| Q3 24 | $274.3M | $40.6M | ||
| Q2 24 | $300.1M | $43.2M | ||
| Q1 24 | $234.3M | $36.2M |
| Q4 25 | $-185.8M | — | ||
| Q3 25 | $-238.2M | — | ||
| Q2 25 | $-199.2M | $119.9M | ||
| Q1 25 | $-238.2M | $25.0M | ||
| Q4 24 | $-202.6M | $-456.0K | ||
| Q3 24 | $-171.9M | $-23.5M | ||
| Q2 24 | $-131.7M | $-31.2M | ||
| Q1 24 | $-194.4M | $-31.7M |
| Q4 25 | $323.1M | — | ||
| Q3 25 | $289.8M | — | ||
| Q2 25 | $321.6M | $175.1M | ||
| Q1 25 | $272.5M | $98.5M | ||
| Q4 24 | $322.0M | $120.5M | ||
| Q3 24 | $349.1M | $139.0M | ||
| Q2 24 | $371.8M | $159.2M | ||
| Q1 24 | $308.0M | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.1M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.1M | — | ||
| Q3 25 | $-29.6M | — | ||
| Q2 25 | $-24.1M | $-15.8M | ||
| Q1 25 | $-56.3M | $-21.0M | ||
| Q4 24 | $-21.9M | $-19.9M | ||
| Q3 24 | $-25.0M | $-20.7M | ||
| Q2 24 | $-32.8M | $-19.5M | ||
| Q1 24 | $-44.1M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | $-56.6M | $-21.2M | ||
| Q4 24 | $-21.9M | $-20.0M | ||
| Q3 24 | $-25.3M | $-20.7M | ||
| Q2 24 | $-32.9M | $-19.6M | ||
| Q1 24 | $-44.6M | $-26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | -325.2% | -41.6% | ||
| Q4 24 | -129.8% | -52.5% | ||
| Q3 24 | -140.2% | -62.1% | ||
| Q2 24 | -193.0% | -78.2% | ||
| Q1 24 | -250.0% | -63.1% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 1.2% | 0.1% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 3.0% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADCT
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
